The role of iron in doxorubicin-induced cardiotoxicity: recent advances and implication for drug delivery. Issue 24 (1st June 2021)

• Record Type: Journal Article
• Authors: Qin, Yan; Guo, Tao; Wang, Zheng; Zhao, Yanjun
• Is Part Of: Journal of materials chemistry. Volume 9:Issue 24(2021)
• Page Start: 4793
• Page End: 4803
• Publication Date: 2021-06-01
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/d1tb00551k
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Doxorubicin administration induces the impairment of iron homeostasis and ferroptosis of cardiomyocytes. The delivery of iron chelators and radical trapping agents could inhibit ferroptotic cell death to relieve doxorubicin-induced cardiotoxicity. Abstract : As an anthracycline antibiotic, doxorubicin (DOX) is one of the most potent and widely used chemotherapeutic agents for treating various types of tumors. Unfortunately, the clinical application of this drug results in severe side effects, particularly dose-dependent cardiotoxicity. There are multiple mechanisms involved with the cardiotoxicity caused by DOX, among which intracellular iron homeostasis plays an essential role based on a recent discovery. In this mini-review, we summarize the clinical features and symptoms of DOX-dependent cardiotoxicity, discuss the correlation between iron and cardiotoxicity, and highlight the involvement of iron-dependent ferroptotic cell death therein. Recent advances in this topic will aid the development of novel DOX delivery systems with reduced adverse effects, and expand the clinical application of anthracycline.